Dissection of differences and similarities of botanical drugs in European Union, US and Canada.
- Author:
Yi HE
1
;
Libin ZHAO
;
Zhengliang YE
;
Zhixin GUO
;
He SUN
Author Information
1. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China.
- Publication Type:Journal Article
- MeSH:
Canada;
Drug and Narcotic Control;
history;
organization & administration;
European Union;
organization & administration;
Herbal Medicine;
history;
legislation & jurisprudence;
organization & administration;
History, 20th Century;
History, 21st Century;
Humans;
Phytotherapy;
standards;
Plants, Medicinal;
chemistry;
United States
- From:
China Journal of Chinese Materia Medica
2011;36(19):2747-2750
- CountryChina
- Language:Chinese
-
Abstract:
Because of the unique nature and treatment concept of traditional Chinese medicines (TCMs), TCMs have been respected again since 70s of last century. The regulatory agencies of some developed countries (the FDA, EMA and Health Canada etc) have published new guidance/guidelines/directives in recent years, such as the botanical drug product guidance of the FDA, the evidence for quality of finished natural health products guidance of the Health Canada and the guideline on quality of herbal medicinal products/ traditional herbal medicinal products of the EMA etc. All of the regulatory agencies are willing to scientifically evaluate the herbal medicines and accept it as therapeutic product. This paper analyzed the history of herbal medicine regulation and the similarities and differences of the regulatory requirements of the European Union, the United States and Canada, proposed possible future direction of the international development of Chinese medicine from the perspective of global regulatory affairs.
